**5. Conclusions**

The dynamic whole-body acquisition of [18F]FDG using the Patlak plot was shown to be a stable method for the determination of whole-body glucose metabolism dynamics that operates well in routine clinical practice even on a standard PET/CT scanner. The quantification of the MR-FDG detects malignant lung tumors, LNM, and distant metastases with at least comparable accuracy as the established SUVmean or time-consuming dual-time-point PET scans. In contrast to MR FDG, which correlates strongly with SUV, the distribution volume (DV) of [18F]FDG was considerably higher in liver metastases, indicating a potential additional benefit for the Patlak parameter DV-FDG in detecting hepatic metastases.

**Supplementary Materials:** The following supporting information can be downloaded at: https:// www.mdpi.com/article/10.3390/jcm12123942/s1. Table S1: Extended AUC values of pulmonary lesions (n = 32, prevalence: 52.4%). Table S2: Extended AUC values of thoracic lymph nodes (n = 65, prevalence: 18.5%).

**Author Contributions:** Conceptualization, C.l.F., H.D., M.W. and K.N.; methodology, C.l.F., M.W. and H.D.; software, S.C.-V. and S.V.B.; validation, M.E.C., A.M.S., C.l.F. and H.D.; formal analysis, M.W. and C.l.F.; investigation, M.A., L.Z. and H.D.; resources, K.N. and C.l.F.; data curation, M.A., W.S. and M.W.; writing—original draft preparation, M.W., S.V.B. and C.l.F.; writing—review and editing, F.S., A.M.S., M.E.C. and H.D.; visualization, M.W.; supervision, L.Z., C.l.F. and K.N.; project administration, L.Z., W.S., C.l.F. and K.N.; funding acquisition, C.l.F. and K.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Kennedyallee 40, 53175 Bonn) under Germany's Excellence Strategy (EXC 2180–390900677).

**Institutional Review Board Statement:** This prospective trial was approved by the institutional review board (registry No. 333/2019BO2) and is listed in the German Clinical Trial Register (DRKS-ID: DRKS00017717). All patients signed an informed consent.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to data protection regulations.

**Acknowledgments:** We acknowledge support from the Open Access Publishing Fund of the University of Tübingen.

**Conflicts of Interest:** Anne M. Smith and Michael E. Casey are full-time employees of Siemens Medical Solutions USA, Inc. The authors declare that they did not inappropriately influence the presentation or interpretation of the research results. The authors declare no further conflict of interest.
